secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xenon Pharmaceuticals Inc. (XENE)
CIK:        0001582313
Form:       8-K
Filed at:   2022-11-07T23:59:59+00:00
Accession:  0000950170-22-022588
Event type: leadership
Sentiment:  neutral
Materiality: 0.45
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Xenon Pharma appoints Andrea DiFabio as Chief Legal Officer and Corporate Secretary
--------------------------------------------------------------------------------

- Andrea DiFabio joined Xenon as Chief Legal Officer and Corporate Secretary effective Nov 7, 2022.
- She previously served as Chief Legal & Admin Officer at Repertoire Immune Medicines (2020-2022).
- DiFabio held CLO roles at Codiak Biosciences and Bioverativ; earlier experience at Biogen and Parexel.
- She will lead global legal strategy as Xenon advances late-stage epilepsy clinical programs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1582313/000095017022022588/0000950170-22-022588-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1582313/000095017022022588/xene-20221107.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-022588

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer